• Progression Free Survival [ Time Frame: 180 days without evidence of disease progression would be considered clinically worthy of further investigation ]
  

• -PSA Response -Toxicity [ Time Frame: The secondary endpoint of PSA response will also be documented. PSA response is defined as a ≥50% fall in PSA (minimum of 5 µg/L) from baseline maintained for > 3 weeks and without evidence of disease progression otherwise. ]
  

Drug: Sunitinib (SU011248)
SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression

Inclusion Criteria:

• Histological or cytological diagnosis of adenocarcinoma of the prostate
• Metastatic or locally recurrent disease not curable with standard therapy
• ECOG performance status 0, 1 or 2
• Prior single agent docetaxel or docetaxel combination chemotherapy with a documented PSA or imaging response, and no objective evidence of disease progression at study enrolment

Exclusion Criteria:

• Patients with a history of other invasive cancer, except adequately treated non
• melanoma skin cancer.
• Patients with known brain metastases.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to SU011248.
• Other serious intercurrent illness or medical condition that might be aggravated by protocol treatment.